Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 2, pp 285–291 | Cite as

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability

  • Kyu-pyo Kim
  • Min-Hee Ryu
  • Changhoon Yoo
  • Baek-Yeol Ryoo
  • Dae Ro Choi
  • Heung Moon Chang
  • Jae-Lyun Lee
  • Mo Youl Beck
  • Tae Won Kim
  • Yoon-Koo Kang
Original Article
First Online:
Received:
Accepted:

Abstract

Purpose

To evaluate the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors (GISTs) resistant or intolerant to both imatinib and sunitinib and to explore the potential relationship between nilotinib pharmacokinetics and clinical outcomes.

Patients and methods

We analyzed the efficacy, tolerability and pharmacokinetic parameters of nilotinib (400 mg twice daily) in 17 GIST patients with histories of prior gastrointestinal surgery.

Results

Median patient age was 59 years (range, 35–71 years), 14 of 17 patients (82.4%) were male, and mean body weight was 59.4 kg. Of the 17 patients, 2 (11.8%) had partial responses (PR), 10 (58.8%) had stable disease (SD), and 5 (29.4%) had progressive disease (PD), with a clinical benefit rate (CR + PR + SD) at 24 weeks of 47.0%. Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0–50.6 weeks) and 74.0 weeks (95% CI 27.4–120.6 weeks), respectively. Most observed adverse events were mild (grade 1, 41.2%; grade 2, 52.9%), with no grade 3/4 events. Pharmacokinetic parameters of nilotinib were as follows: C max of 1,754 ± 970 μg/L, T1/2 of 13.4 ± 8.94 h and AUC 0–12 h of 14,190 ± 6,853 h μg/L. The AUC 0–12 h of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 ± 7,869 h μg/L vs. 15,930 ± 5,759 h μg/L, P = 0.014). Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC 0–12 h of 1,914 and 3,194 h μg/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).

Conclusion

Nilotinib was active and safe in patients with advanced GIST resistant to both imatinib and sunitinib. Major gastrectomy decreased the bioavailability of nilotinib and, in some patients, lowered its clinical activity.

Keywords

Pharmacokinetics Nilotinib Gastrointestinal stromal tumor Gastrectomy 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors are grateful to all the staff who contributed to this study.

Conflict of interest

YKK has received an honorarium from Novartis.

References

  1. 1.
    Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632PubMedCrossRefGoogle Scholar
  2. 2.
    Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRefGoogle Scholar
  3. 3.
    Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134PubMedCrossRefGoogle Scholar
  4. 4.
    Demetri GD, Benjamin RS, Blanke CD et al (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2):S1–S29 (quiz S30)PubMedGoogle Scholar
  5. 5.
    Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367–1373PubMedCrossRefGoogle Scholar
  6. 6.
    Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774PubMedCrossRefGoogle Scholar
  7. 7.
    Wardelmann E, Merkelbach-Bruse S, Pauls K et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12:1743–1749PubMedCrossRefGoogle Scholar
  8. 8.
    Theou-Anton N, Faivre S, Dreyer C, Raymond E (2009) Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf 32:717–734PubMedCrossRefGoogle Scholar
  9. 9.
    Manley PW, Drueckes P, Fendrich G et al (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445–453PubMedGoogle Scholar
  10. 10.
    Prenen H, Guetens G, de Boeck G et al (2006) Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 77:11–16PubMedCrossRefGoogle Scholar
  11. 11.
    le Coutre P, Ottmann OG, Giles F et al (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834–1839PubMedCrossRefGoogle Scholar
  12. 12.
    Sevinc A (2009) Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report. Chemotherapy 55:132–136PubMedCrossRefGoogle Scholar
  13. 13.
    Montemurro M, Schoffski P, Reichardt P et al (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 45:2293–2297PubMedCrossRefGoogle Scholar
  14. 14.
    Tanaka C, Yin OQ, Sethuraman V et al (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197–203Google Scholar
  15. 15.
    Yoo C, Ryu MH, Kang BW et al (2010) Cross-Sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 556:43–46Google Scholar
  16. 16.
    Choi H, Charnsangavej C, de Castro Faria S et al (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183:1619–1628PubMedGoogle Scholar
  17. 17.
    Linton KM, Taylor MB, Radford JA (2006) Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 79:e40–e44PubMedCrossRefGoogle Scholar
  18. 18.
    Ryu MH, Lee JL, Chang HM et al (2006) Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol 36:17–24PubMedCrossRefGoogle Scholar
  19. 19.
    Demetri GD, Casali PG, Blay JY et al (2009) A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 15:5910–5916PubMedCrossRefGoogle Scholar
  20. 20.
    Yin OQ, Gallagher N, Li A et al (2010) Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 50:188–194Google Scholar
  21. 21.
    Gallagher NJ, Fischer D, Demirhan E et al (2009) Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Oncol 27(15S):7053Google Scholar
  22. 22.
    Deininger MW (2008) Nilotinib. Clin Cancer Res 14:4027–4031PubMedCrossRefGoogle Scholar
  23. 23.
    Pavlovsky C, Egorin MJ, Shah DD et al (2009) Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. Pharmacotherapy 29:1152–1156PubMedCrossRefGoogle Scholar
  24. 24.
    Demetri GD, Wang Y, Wehrle E et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141–3147PubMedCrossRefGoogle Scholar
  25. 25.
    Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496–3499PubMedCrossRefGoogle Scholar
  26. 26.
    Haouala A, Zanolari B, Rochat B et al (2009) Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:1982–1996PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Kyu-pyo Kim
    • 1
  • Min-Hee Ryu
    • 1
  • Changhoon Yoo
    • 1
  • Baek-Yeol Ryoo
    • 1
  • Dae Ro Choi
    • 1
  • Heung Moon Chang
    • 1
  • Jae-Lyun Lee
    • 1
  • Mo Youl Beck
    • 1
  • Tae Won Kim
    • 1
  • Yoon-Koo Kang
    • 1
  1. 1.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea

Personalised recommendations